<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04708106</url>
  </required_header>
  <id_info>
    <org_study_id>RELX-003</org_study_id>
    <nct_id>NCT04708106</nct_id>
  </id_info>
  <brief_title>Characterization of Product Use in Smokers Switching From Cigarettes to a RELX Electronic Nicotine Delivery System</brief_title>
  <official_title>A Randomized, Multi-Center, Open-Label, Parallel-Cohort Study to Characterize Product Use in Smokers Switching From Combustible Cigarettes to a RELX Electronic Nicotine Delivery System (ENDS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cheerain HK Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cheerain HK Limited</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study will assess product use behaviors, biomarkers of exposure, subjective effects, and&#xD;
      safety in smokers who switch to a RELX ENDS over 8-weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 15, 2020</start_date>
  <completion_date type="Actual">July 7, 2021</completion_date>
  <primary_completion_date type="Actual">July 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Weekly RELX ENDS product use</measure>
    <time_frame>56 days</time_frame>
    <description>Self-reported number of RELX ENDS pods started each week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Daily number of cigarettes smoked</measure>
    <time_frame>56 days</time_frame>
    <description>Self-reported number of cigarettes smoked daily by study week.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of puffs from the RELX ENDS each day</measure>
    <time_frame>56 days</time_frame>
    <description>Self-reported number of puffs from the RELX ENDS daily by study week (0, &lt; 100, ≥ 100 per day).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of exposure measured in blood</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in carbon monoxide concentration in the blood.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biomarkers of tobacco exposure measured in urine</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in creatinine-adjusted NNAL, NNN, 3-HPMA, CEMA, HMPMA, S-PMA, HEMA, 1-OHP, o-toluidine, nicotine equivalents, and propylene glycol excreted in urine.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects as measured by the Penn State [Electronic] Cigarette Dependence Index (PS[E]CDI)</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Change in product dependence as measured by the PSCDI/PSECDI total score. Total scores may range for 0 to 20, with higher levels of dependence associated with higher scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects as measured by the Cough Questionnaire</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Change in self-reported cough symptoms as measured by responses to the Cough Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects as measured by the Questionnaire of Smoking Urges-Brief (QSU-Brief)</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Change in smoking urge as measured by the QSU-Brief factor 1 and factor 2 scores. Questionnaire responses are measured on a Likert scale range of 1 [not at all] to 7 [extremely].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects as measured by the Minnesota Tobacco Withdrawal Scale-Revised (MTWS-R)</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Change in withdrawal symptoms as measured by the MTWS-R total score, which includes the DSM-5 and craving items from the Minnesota Tobacco Withdrawal Scale. Questionnaire responses are measured on a Likert scale range of 0 [none] to 4 [severe]).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects as measured by the Modified Product Evaluation Scale (mPES)</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Change in product assessments as measured by mPES satisfaction, psychological reward, aversion, and relief subscale scores. Questionnaire responses are measured on a Likert scale range of 1 [not at all] to 7 [extremely].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective effects as measured by the Future Intent to Use Questionnaire</measure>
    <time_frame>Baseline, Day 14, Day 28, Day 42, and Day 56</time_frame>
    <description>Change in future intent to use cigarettes and ENDS products as measured by responses to the Future Intent to Use Questionnaire. Questionnaire responses are measured on a Likert scale range of 1 [extremely unlikely] to 7 [extremely likely].</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subjective Effects as measured by the Health Effects Perceptions Questionnaire</measure>
    <time_frame>Baseline and Day 56</time_frame>
    <description>Harmful and addictiveness perceptions as measured by responses to the Health Effects Perceptions Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puff topography - number of puffs</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in the number of puffs during a 1-hour puff topography session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puff topography - puff duration</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in puff duration during a 1-hour puff topography session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puff topography - puff volume</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in puff volume during a 1-hour puff topography session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puff topography - peak puff flow rate</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in peak puff flow rate during a 1-hour puff topography session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puff topography - average flow rate</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in average flow rate during a 1-hour puff topography session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Puff topography - inter-puff interval</measure>
    <time_frame>Baseline, Day 28, and Day 56</time_frame>
    <description>Change in inter-puff interval during a 1-hour puff topography session.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RELX ENDS product use</measure>
    <time_frame>Day 28 and Day 56</time_frame>
    <description>Change in pod weight during a 1-hour topography session</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of product-use emergent adverse events [Safety and Tolerability]</measure>
    <time_frame>56 days</time_frame>
    <description>Incidence of product-use emergent adverse events</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">194</enrollment>
  <condition>Electronic Cigarette Use</condition>
  <arm_group>
    <arm_group_label>RELX ENDS Tobacco Flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch from combustible cigarettes to RELX ENDS Tobacco Flavor for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RELX ENDS Menthol Flavor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch from combustible cigarettes to RELX ENDS Menthol Flavor for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RELX ENDS Tobacco and Menthol Flavors</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Switch from combustible cigarettes to RELX ENDS Tobacco and Menthol Flavor for 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Continue-smoking</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Continue smoking combustible cigarettes for 56 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RELX ENDS Tobacco Flavor</intervention_name>
    <description>Ad libitum use of the RELX ENDS Tobacco Flavor product</description>
    <arm_group_label>RELX ENDS Tobacco Flavor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RELX ENDS Menthol Flavor</intervention_name>
    <description>Ad libitum use of the RELX ENDS Menthol product</description>
    <arm_group_label>RELX ENDS Menthol Flavor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>RELX ENDS Tobacco and Menthol Flavors</intervention_name>
    <description>Ad libitum use of the RELX ENDS Tobacco and Menthol Flavor products</description>
    <arm_group_label>RELX ENDS Tobacco and Menthol Flavors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Provides voluntary consent to participate in the study as documented on the signed&#xD;
             informed consent form (ICF).&#xD;
&#xD;
          2. Is 22 to 65 years of age, inclusive, at the time of consent.&#xD;
&#xD;
          3. Is willing to comply with the requirements of the study.&#xD;
&#xD;
          4. Reports typically smoking 5 or more combustible CPD at Screening.&#xD;
&#xD;
          5. Has been a daily smoker for at least 12 months prior to Screening. Brief periods of&#xD;
             non-smoking (e.g., up to ~7 consecutive days due to illness, trying to quit,&#xD;
             participation in a study where smoking was prohibited) ≥ 56 days prior to Screening&#xD;
             will be permitted at the discretion of the Investigator.&#xD;
&#xD;
          6. Has a positive urine cotinine test (≥ 200 ng/mL) at Screening and Test Visit 1.&#xD;
&#xD;
          7. Has an exhaled carbon monoxide (ECO) value &gt; 10 ppm at Screening and Test Visit 1.&#xD;
&#xD;
          8. Has daily access to a cell phone for daily product use reporting.&#xD;
&#xD;
          9. If female, meets one of the following criteria:&#xD;
&#xD;
        If of childbearing potential - agrees to use one of the accepted contraceptive regimens&#xD;
        from at least 30 days prior to the first product use and during the study. An acceptable&#xD;
        method of contraception includes one of the following:&#xD;
&#xD;
          -  Abstinence from heterosexual intercourse&#xD;
&#xD;
          -  Hormonal contraceptives (birth control pills, injectable/implant/insertable hormonal&#xD;
             birth control products, transdermal patch)&#xD;
&#xD;
          -  Intrauterine device (with or without hormones) OR agrees to use a double barrier&#xD;
             method (e.g. condom and spermicide) during the study.&#xD;
&#xD;
        If a female of non-childbearing potential - should be surgically sterile (i.e. has&#xD;
        undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation) or in a&#xD;
        menopausal state (at least 1 year without menses), as confirmed by follicle stimulating&#xD;
        hormone (FSH) levels.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Has a history or presence of clinically significant uncontrolled gastrointestinal,&#xD;
             renal, hepatic, neurologic, hematologic, endocrine, oncologic, urologic, pulmonary,&#xD;
             immunologic, psychiatric, or cardiovascular disease, or any other condition that, in&#xD;
             the opinion of the Investigator, would jeopardize the safety of the subject or impact&#xD;
             the validity of the study results.&#xD;
&#xD;
          2. Has a clinically significant abnormal finding on the physical examination, medical&#xD;
             history, vital signs, electrocardiogram (ECG), or clinical laboratory results, in the&#xD;
             opinion of the Investigator.&#xD;
&#xD;
          3. Has a positive test for human immunodeficiency virus (HIV), hepatitis B surface&#xD;
             antigen (HBsAg), or hepatitis C virus (HCV) at Screening.&#xD;
&#xD;
          4. Has a positive COVID-19 test at Screening or during the study.&#xD;
&#xD;
          5. Has had an acute illness (e.g., upper respiratory infection, viral infection) within&#xD;
             14 days prior to Test Visit 1.&#xD;
&#xD;
          6. Has a fever (&gt; 100.5°F) at Screening or Test Visit 1.&#xD;
&#xD;
          7. Has a body mass index (BMI) greater than 40.0 kg/m2 or less than 18.0 kg/m2 at&#xD;
             Screening.&#xD;
&#xD;
          8. Has a systolic blood pressure &lt; 90 mmHg or &gt; 150 mmHg, diastolic blood pressure &lt; 40&#xD;
             mmHg or &gt; 95 mmHg, or heart rate &lt; 40 bpm or &gt; 99 bpm at Screening.&#xD;
&#xD;
          9. Has a post-bronchodilator forced expiratory volume in 1 second:forced vital capacity&#xD;
             (FEV1:FVC) ratio &lt; 0.7 and FEV1 &lt; 50% of predicted at Screening.&#xD;
&#xD;
         10. Has a post-bronchodilator FEV1 increase ≥ 12% and &gt; 200 mL from pre- to&#xD;
             post-bronchodilator at Screening.&#xD;
&#xD;
         11. Has used an ENDS product on &gt;7 days during each of the 3 months prior to Screening or&#xD;
             any use from Screening to Test Visit 1 other than as may be required for this study.&#xD;
&#xD;
         12. Reports use of a very-low nicotine content cigarette (e.g., Moonlight, Spectrum, VLN)&#xD;
             as usual brand.&#xD;
&#xD;
         13. Has used nicotine-containing products other than manufactured cigarettes (e.g., ENDS&#xD;
             products (e-cigarettes), roll-your-own cigarettes, bidis, snuff, nicotine inhaler,&#xD;
             pipe, cigar, chewing tobacco, nicotine patch, nicotine spray, nicotine lozenge, or&#xD;
             nicotine gum) within 14 days prior to Test Visit 1.&#xD;
&#xD;
         14. Has used any products for the purpose of smoking cessation, including, but not limited&#xD;
             to, nicotine replacement therapies, varenicline (Chantix), or buproprion (Zyban) from&#xD;
             30 days prior to Screening through the duration of the study.&#xD;
&#xD;
         15. Is a self-reported puffer (i.e., draws smoke from the cigarette into the mouth and&#xD;
             throat but does not inhale).&#xD;
&#xD;
         16. Is postponing a planned smoking quit attempt in order to participate in the study.&#xD;
&#xD;
         17. Has a history of drug or alcohol abuse within 12 months prior to Screening, as&#xD;
             determined by the Investigator.&#xD;
&#xD;
         18. Is allergic to PG or glycerin.&#xD;
&#xD;
         19. Has a positive urine drug or alcohol breath test at Screening or Test Visit 1. At the&#xD;
             discretion of the investigator, a subject testing positive for tetrahydrocannabinol&#xD;
             may be permitted to participate if the subject reports use by routes other than&#xD;
             inhalation.&#xD;
&#xD;
         20. If female, the subject is pregnant, breastfeeding, or intends to become pregnant from&#xD;
             Screening through the duration of the study.&#xD;
&#xD;
         21. Has been treated for depression, diabetes, asthma, emphysema, or chronic obstructive&#xD;
             pulmonary disease within 12 months prior to Test Visit 1.&#xD;
&#xD;
         22. Has previously been diagnosed with any form of cancer, except for basal cell or&#xD;
             squamous epithelial carcinomas of the skin that have been resected at least 12 months&#xD;
             prior to Screening 1.&#xD;
&#xD;
         23. Has a planned surgery that would occur during study participation.&#xD;
&#xD;
         24. Has participated in a previous clinical study for an investigational drug, device,&#xD;
             biologic, or tobacco product within 30 days prior to Test Visit 1.&#xD;
&#xD;
         25. Is or has a first-degree relative (e.g., spouse, parent, sibling, or child) who is a&#xD;
             current or former employee of a tobacco or ENDS manufacturer or is a named party or&#xD;
             class representative in litigation with the tobacco or ENDS industry.&#xD;
&#xD;
         26. Is or has a first-degree relative (e.g., spouse, parent, sibling, or child) who is a&#xD;
             current employee of the clinic site.&#xD;
&#xD;
         27. Is or has a first-degree relative (e.g., spouse, parent, sibling, or child) who is a&#xD;
             current employee of the Sponsor.&#xD;
&#xD;
         28. Has previously taken part in (from completion of any baseline measurements), has been&#xD;
             withdrawn from, or has completed this study.&#xD;
&#xD;
         29. In the opinion of the Investigator, the subject should not participate in this study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Donald Graff, PharmD</last_name>
    <role>Study Director</role>
    <affiliation>Sponsor Representative</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mark Adams, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMR - Lexington</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pillar Clinical Research</name>
      <address>
        <city>Bentonville</city>
        <state>Arkansas</state>
        <zip>72712</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR - Lexington</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40509</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>QPS</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR - Las Vegas</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89119</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AMR - Knoxville</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37920</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>January 8, 2021</study_first_submitted>
  <study_first_submitted_qc>January 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 13, 2021</study_first_posted>
  <last_update_submitted>July 20, 2021</last_update_submitted>
  <last_update_submitted_qc>July 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Electronic Nicotine Delivery System</keyword>
  <keyword>Biomarkers</keyword>
  <keyword>Subjective Effects</keyword>
  <keyword>Topography</keyword>
  <keyword>E-cigarette</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Menthol</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

